Q2 2026 Vertex Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vertex Pharmaceuticals Inc (VRTX) reported strong second-quarter 2026 results with total revenue growing 12% year-over-year, driven by robust performance in its cystic fibrosis portfolio and contributions from newer products like CASGEVY and JOURNAVX.
- The company's CF franchise continues to lead, with ALYFTREK exceeding $1 billion in revenue in the first half of 2026 and showing strong uptake in the US and Europe, including rapid adoption in Germany and the UK.
- CASGEVY momentum is building, with revenue of $76 million in Q2 2026, a 75% sequential increase, and more infusions in the first half of 2026 than in all of 2025, supported by expanded pediatric approvals and strong reimbursement agreements.
- JOURNAVX is gaining traction with Q2 revenue of $50 million, sequential growth of 70%, and prescription growth of 45%, with over 535,000 prescriptions in the quarter and expanding payer coverage to 260 million lives.
- The pipeline is advancing rapidly, including the FDA acceptance of the BLA for povetacicept in IgAN with a November 30 PDUFA date, completion of enrollment in the GLO Phase 2 study for VX-407 in ADPKD, and the clearance of the IND for VX-017, a universal donor islet cell therapy for type 1 diabetes.
- The proposed acquisition of Crinetics Pharmaceuticals is expected to add a fifth pillar in rare endocrine diseases, with a peak sales opportunity of about $5 billion, and is expected to be accretive to non-GAAP operating income by 2029.
- Gross margin declined sequentially to 85.6% in Q2 2026, reflecting product mix and manufacturing network investments, with expectations of further pressure in the second half of the year.
- SG&A expenses increased 45% year-over-year due to commercial investments in pain and renal launches, which could pressure near-term profitability.
- JOURNAVX revenue is impacted by higher-than-expected use of the PSP program due to payer restrictions, leading to a delay in gross-to-net normalization to the first half of 2027.
- The company faces high competition in the IgAN space, with competitors showing strong eGFR stabilization data, which could impact povetacicept's market share despite its promising profile.
- The type 1 diabetes program experienced a voluntary pause for manufacturing analysis, and the timeline for launching zimislecel or VX-017 remains uncertain, with plans to be updated later this year.
- The Crinetics acquisition, while strategic, will add to operating expenses and is not expected to be accretive until 2029, potentially diluting near-term earnings.
Good day and welcome to the Vertex Pharmaceuticals second quarter 2026 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead.
Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our Second Quarter 2026 Financial Results Conference Call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Charlie Wagner, Chief Operating Officer and Chief Financial Officer; and Duncan McKechnie, Chief Commercial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
